Zhejiang Tuberculosis Diagnosis and Treatment Center, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
PLoS One. 2021 Mar 11;16(3):e0247494. doi: 10.1371/journal.pone.0247494. eCollection 2021.
Small cell lung cancer (SCLC) is a highly malignant lung cancer with a very poor prognosis. Clinical treatment options for SCLC are still limited, especially for patients who have failed first or second line therapy. Anlotinib is a potentially beneficial new treatment option for SCLC. The aim of this meta-analysis is to evaluate the efficacy and safety of anlotinib-containing regimen for the treatment of SCLC.
We will search SinoMed, Wanfang Database, China National Knowledge Infrastructure, Embase, Cochrane Library, and PubMed for relevant articles that may meet the criteria published before March 31, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of anlotinib-containing regimen for the treatment of SCLC. Clinical randomized controlled trials comparing anlotinib-containing regimens with other treatment regimens for advanced SCLC will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data.
The results of this study will provide evidence of anlotinib-containing regimens for advanced SCLC, and provide clinicians and patients with another convenient and effective treatment regimen for SCLC. This meta-analysis will be submitted to a peer-reviewed journal for publication.
This meta-analysis will provide clinical evidence of anlotinib-containing regimens for advanced SCLC, which may or may not be found for anlotinib use.
INPLASY202110034.
小细胞肺癌（SCLC）是一种高度恶性的肺癌，预后极差。SCLC 的临床治疗选择仍然有限，特别是对于一线或二线治疗失败的患者。安罗替尼是一种有前途的治疗 SCLC 的新选择。本荟萃分析旨在评估含安罗替尼方案治疗 SCLC 的疗效和安全性。
我们将检索中国生物医学文献数据库、万方数据库、中国知网、Embase、 Cochrane Library 和 PubMed，以获取截至 2021 年 3 月 31 日之前可能符合标准的相关文章。我们将进行荟萃分析，以评估含安罗替尼方案治疗 SCLC 的疗效和安全性。本研究将纳入比较含安罗替尼方案与其他治疗方案治疗晚期 SCLC 的临床随机对照试验。将使用 Cochrane 干预系统评价手册对纳入的每项研究进行偏倚风险评估。我们将使用 RevMan 5.3 软件对数据进行统计分析。
本研究的结果将为晚期 SCLC 提供含安罗替尼方案的证据，并为临床医生和患者提供另一种方便有效的 SCLC 治疗方案。本荟萃分析将提交给同行评议期刊发表。
本荟萃分析将为晚期 SCLC 提供含安罗替尼方案的临床证据，可能会也可能不会发现安罗替尼的应用。
INPLASY202110034。
